Floatz logo

Irradiated Allogeneic Cells

Minimal Residual Disease

Rutgers, The State University of New JerseyCell therapyEarly Phase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
73/ 100

Competitive context

51 Active assets in the Minimal Residual Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
FILGRASTIM
Masonic Cancer Center, University of Minnesota
Phase 2/3BB
Piritramide
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4B
DEXAMETHASONE
Instituto do Cancer do Estado de São Paulo
Phase 4B
LIDOCAINE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4B

View all 50 →

Same molecule, other indications

Irradiated Allogeneic Cells is also rated in:

acute myeloid leukemiaDormant
C
Indicative ·
39 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
C
Indicative ·
39 / 100
View asset →
myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2Dormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →